Bilastine is a peripheral histamine H1-antagonist used to treat seasonal allergic rhinitis and chronic spontaneous urticaria. Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
- Mechanism
- Curator reviewed
Bilastine is a selective histamine H1 receptor antagonist (Ki = 64nM). During allergic response mast cells undergo degranulation which releases histamine and other subastances. By binding to and preventing activation of the H1 receptor, bilastine reduces the development of allergic symptoms due to the release of histamine from mast cells.
- Primary indication
- For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older.Curator reviewed · 2 structured indications
- Formula / weight
- C28H37N3O3 · 463.622 g/mol (avg)
- First approval
- Canada, 2018
- Brand names
Resolves to
ACCMWZWAEFYUGZ-UHFFFAOYSA-NSMILESCCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1What you can answer from here — as of March 06, 2025
Which drugs share a target with Bilastine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account